tipFebruary 8, 2021 40
The global skin tightening market is expected to reach US$ 2,350.22 million in 2027 from US$ 1,350.40 million in 2019. The market is estimated to grow with a CAGR of 7.3% from 2020 to 2027.
Download Sample Copy of This Report @
The growth of the market is attributed to some key driving factors such as increasing cosmetic procedures, and growing aging population. However, high cost of cosmetic procedures is expected to hamper the growth of the market to a certain extent during the forecast years.
Market Insights
Skin tightening procedures include minimally invasive cosmetic procedures such as face lifts and wrinkle reduction that change the external appearance of the person. Minimal invasiveness lessens the complications associated with the procedures, further allowing a rapid recovery. The nonsurgical skin tightening treatments can be offered in the form of in-office procedures or at-home devices.
Posted on 1116
Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) has gained further validation for Myriad™, a device for soft tissue reconstruction, with two studies published in successive months in a leading peer reviewed scientific journal, Journal of Wound Care, official journal of the European Wound Management Association (EWMA) and World Union of Wound Healing Societies (WUWHS).
A study published in the November 2020 edition of Journal of Wound Care showed 100% healing when Myriad™ was used in eight surgical reconstructions to address inflammatory skin condition Hidradenitis Suppurativa (HS). No major complications were reported out to three months, or longer.
Share:
HIGHLIGHTS
Further validation for Aroa s Myriad™ from two clinical studies and peer-reviewed publications in Journal of Wound Care.
One study shows high success rates, from use of Myriad™ in tissue reconstruction after surgical treatment of Hidradenitis Suppurativa, an inflammatory skin condition affecting around 1% of the adult population.
A second study showed 100% success rates from use of Myriad™ when patients underwent surgical reconstruction of exposed vital structures such as bone and tendon, demonstrating the utility of Myriad™ for both implant procedures and dermal reconstruction and across a wide range of surgical procedures.
The national regulatory authority of India, the Central Drugs Standard Control Organisation (CDSCO), has approved Myriad™, Endoform® Natural and Endoform® Antimicrobial. India has significant market potential with a large volume of acute and chronic wounds and distribution expected to commence in second half of the 2021 calendar